Summit Therapeutics Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-01-08: Reporting owner Anand Bhaskar; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-01-02: Reporting owner Zanganeh Mahkam; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-01-02: Reporting owner DUGGAN ROBERT W; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-01-02: Reporting owner Booth Robert F.; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
SMMT insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | Anand Bhaskar Officer (Chief Accounting Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $18.83 exercise price | $18.83 | 2026-01-12 |
| 2026-01-02 | Zanganeh Mahkam Director, Officer (Co-Chief Executive Officer), 10% Owner | 4 | Stock Option (right to buy) Derivative · Indirect · By Spouse | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,232 11,232 owned after | $8.76 | $17.52 | 2026-01-06 |
| 2026-01-02 | DUGGAN ROBERT W Director, Officer (Co-Chief Executive Officer), 10% Owner | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +11,232 11,232 owned after | $8.76 | $17.52 | 2026-01-06 |
| 2026-01-02 | Booth Robert F. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Booth Robert F. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,180 7,180 owned after | $8.76 | $17.52 | 2026-01-06 |
| 2026-01-02 | Xia Yu Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Huber Jeff Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Huber Jeff Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,885 9,885 owned after | $8.76 | $17.52 | 2026-01-06 |
| 2026-01-02 | Ronaghi Mostafa Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Clark Kenneth A Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Clark Kenneth A Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,796 17,796 owned after | $8.76 | $17.52 | 2026-01-06 |
| 2026-01-02 | Cesano Alessandra Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $17.52 exercise price | $17.52 | 2026-01-06 |
| 2026-01-02 | Cesano Alessandra Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,219 3,219 owned after | $8.76 | $17.52 | 2026-01-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |